Millennium Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Millennium Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,000	Closed	-$114K	–	5835
2024 Q1	$114K	Sell	40,000 -161,200	-80%	-$2.11M	﹤0.01%	5545
2023 Q4	$2.96M	Buy	201,200 +156,200	+347%	+$2.39M	﹤0.01%	3261
2023 Q3	$824K	Buy	+45,000	New	+$952K	﹤0.01%	4318
2023 Q2	–	Sell	-30,000	Closed	-$880K	–	6071
2023 Q1	$880K	Buy	30,000 +3,500	+13%	+$122K	﹤0.01%	4205
2022 Q4	$979K	Sell	26,500 -144,800	-85%	-$5.14M	﹤0.01%	4188
2022 Q3	$4.82M	Buy	171,300 +140,000	+447%	+$3.49M	﹤0.01%	2921
2022 Q2	$603K	Buy	+31,300	New	+$372K	﹤0.01%	4802

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Millennium Management's AMLX Position: Q1 2026 in Review

Millennium Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 46,455 shares — an estimated $561K sold.

Millennium Management first reported a position in AMLX in Q1 2022 and held it in 16 quarters. The position peaked at $41.4M in Q2 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Millennium Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 46,455 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $561K.
Millennium Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 16 quarters.
Millennium Management's Amylyx Pharmaceuticals position peaked at $41.4M in Q2 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.